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Highlights:		Exhausted	CD8	T	cells	show	increased	expression	of	glucose	transporter-1		Functional,	but	not	exhausted	T	cells	can	use	OXPHOS	to	supplement	their	energy	demand		Exhausted	T	cells	harbour	dysfunctional	depolarised	mitochondria			Interleukin-12	can	rescue	mitochondrial	function	and	effector	responses	in	exhausted	CD8			eTOC			T	cells	undergo	extensive	metabolic	changes	upon	activation.		Schurich	et	al	find	that	functional	and	exhausted	human	virus-specific	CD8	T	cells	have	distinct	metabolic	phenotypes,	shaping	their	effector	capacity.		
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Short	title:	Distinct	metabolism	of	functional	and	exhausted	T	cells	
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Abstract		T	 cells	 undergo	 profound	 metabolic	 changes	 to	 meet	 the	 increased	 energy	demands	of	maintaining	an	antiviral	response.	We	postulated	that	differences	in	metabolic	 reprogramming	 would	 shape	 the	 efficacy	 of	 CD8	 T	 cells	 mounted	against	persistent	viral	 infections.	We	 found	that	 the	poorly	 functional	PD-1hi	T	cell	 response	 against	 HBV	 had	 upregulated	 the	 glucose	 transporter,	 Glut1,	 an	effect	 recapitulated	 by	 oxygen	 deprivation	 to	 mimic	 the	 intrahepatic	environment.	 Glut1hi	HBV-specific	 T	 cells	were	 dependent	 on	 glucose	 supplies,	unlike	 the	 more	 functional	 CMV-specific	 T	 cells,	 that	 could	 utilise	 oxidative	phosphorylation	in	the	absence	of	glucose.	 	The	inability	of	HBV-specific	T	cells	to	 switch	 to	 oxidative	 phosphorylation	 was	 accompanied	 by	 increased	mitochondrial	 size	 and	 lower	 mitochondrial	 potential,	 indicative	 of	mitochondrial	 dysfunction.	 IL-12,	 which	 recovers	 HBV-specific	 T	 cell	 effector	function,	increased	their	mitochondrial	potential	and	reduced	their	dependence	on	glycolysis.	Our	findings	suggest	that	mitochondrial	defects	limit	the	metabolic	plasticity	of	exhausted	HBV-specific	T	cells.	
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Introduction		On	average,	humans	are	 infected	with	around	8-12	different	persistent	viruses	during	their	life-time	(Virgin	et	al.,	2009).	Most	of	these	infections,	like	Epstein-Barr	Virus	(EBV)	and	cytomegalovirus	(CMV)	are	benign	in	the	vast	majority	of	human	hosts	and	the	antiviral	T	cell	response	is	adapted	to	keeping	the	virus	at	bay	whilst	limiting	organ	damage.	Other	chronic	infections	such	as	HIV,	hepatitis	C	 virus	 (HCV)	 and	 hepatitis	 B	 virus	 (HBV)	 cannot	 be	 controlled	 by	 the	 T	 cell	response	 once	 persistence	 is	 established,	 often	 resulting	 in	 immunopathology	and	serious	sequelae.		An	estimated	240	million	people	worldwide	are	chronically	 infected	with	HBV,	which	is	the	leading	cause	of	liver	cirrhosis	and	hepatocellular	carcinoma.	CD8	T	cells	are	one	of	the	critical	mediators	of	HBV	clearance,	by	IFNγ	mediated	non-cytopathic	mechanisms,	 possibly	 supported	 by	 direct	 cytotoxicity.	 However	 in	chronic	 HBV	 infection,	 the	 pivotal	 anti-viral	 CD8	 T	 cell	 response	 is	 virtually	absent.	The	few	HBV-specific	T	cells	detectable	are	functionally	exhausted,	with	expression	 of	 multiple	 co-inhibitory	 receptors	 and	 poor	 effector	 function	(Ferrari,	2015),	a	state	that	has	recently	been	suggested	to	allow	them	to	adapt	to	 the	 onslaught	 of	 high-dose	 antigen	 (Staron	 et	 al.,	 2014;	 Utzschneider	 et	 al.,	2013).		In	contrast	T	cells	directed	against	CMV	are	a	prototype	of	a	functional	response	able	 to	efficiently	 contain	 this	highly	prevalent,	persistent	viral	 infection.	CMV-specific	 T	 cells	 can	 readily	 be	 detected	 in	 greatly	 expanded	 numbers,	 with	conserved	clonotypes	often	dominating	the	endogenous	T	cell	repertoire	(Khan	
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et	 al.,	 2002).	 They	 are	 phenotypically	 distinct,	 expressing	 late	 differentiation	markers	 such	 as	 KLRG-1	 rather	 than	 the	 multiple	 co-inhibitory	 receptors	characteristic	of	HBV-specific	T	cells	(Schurich	and	Henson,	2014).	CMV-specific	T	cells	produce	significant	amounts	of	effector	cytokines	such	as	IFNγ	and	TNF	in	response	to	stimulation	with	their	cognate	peptide	in	vitro.			Since	HBV	and	CMV-specific	T	cells	are	both	directed	against	persistent	viruses	but	differ	markedly	in	their	functionality	and	phenotype,	we	were	interested	to	compare	 their	underlying	metabolic	requirements.	 It	 is	 increasingly	recognised	that	 adequate	 nutrient	 supply	 and	 energy	 production	 are	 key	 determinants	 of	the	 capacity	of	T	 cells	 to	proliferate	and	mediate	effector	 function	 (Pearce	and	Pearce,	2013).	Naïve	and	resting	T	cells	make	use	of	fatty	acid	oxidation	and	the	mitochondrial	tricarboxylic	acid	(TCA)	cycle,	which	provides	reducing	agents	for	energy	 production	 through	 oxidative	 phosphorylation	 (OXPHOS)(Pearce	 et	 al.,	2009).	Recently	it	has	been	shown	in	murine	models	that	mitochondrial	activity	is	also	needed	for	activating	and	maintaining	antigen-specific	responses	(Okoye	et	al.,	2015;	Sena	et	al.,	2013).	Upon	activation,	CD8	T	cells	have	been	described	to	switch	 their	metabolism	to	become	heavily	dependent	on	glycolysis,	even	 in	the	presence	of	sufficient	oxygen.	Despite	being	 less	energy	efficient,	glycolysis	provides	 fast	 energy	 and	 metabolites	 to	 support	 proliferation	 and	 effector	function(MacIver	et	al.,	2013).			Many	 recent	 advances	 in	 the	 understanding	 of	 T	 cell	 metabolism	 in	 naïve,	effector	 and	 memory	 stages	 have	 been	 made	 (Pearce	 and	 Pearce,	 2013).	However,	the	current	knowledge	of	T	cell	metabolism	in	chronic	viral	infections	
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is	essentially	 limited	 to	a	single	example,	 the	murine	model	of	LCMV	(Schurich	and	 Henson,	 2014).	 Here	 we	 examine	 the	 metabolic	 requirements	 and	restrictions	of	exhausted	HBV-specific	CD8	T	cells	 to	 the	more	 functional	CMV-specific	T	cells	within	the	same	patients.	Our	data	show	that	CD8	T	cells	specific	for	 these	 two	 chronic	 viral	 infections	 have	 distinct	 metabolic	 profiles.	 CMV-specific	T	cells	can	fuel	their	energetic	demands	by	making	use	of	both	glycolysis	and	OXPHOS	to	exert	full	effector	functions.	In	contrast,	exhausted	HBV-specific	T	 cells	 show	 an	 impaired	 capacity	 to	 utilise	 mitochondrial	 energy	 supply	(OXPHOS),	 causing	 a	 dependence	 on	 glycolysis.	 Their	 defect	 in	 mitochondrial	metabolism	 is	 rescued	 by	 the	 pro-inflammatory	 cytokine	 IL-12,	 which	 can	stimulate	a	recovery	in	HBV-specific	effector	function	(Schurich	et	al.,	2013).	Our	data	 suggest	 that	 full	 effector	 function	 in	 human	 virus-specific	 CD8	 T	 cells	 is	dependent	on	energy	supply	through	both	OXPHOS	and	glycolysis.	
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Results	
Glut-1	expression	is	higher	in	CD8	T	cells	directed	against	HBV	than	CMV	Upon	 TCR	 stimulation	 T	 cells	 markedly	 increase	 the	 expression	 of	 de	 novo	synthesized	 glucose	 transporter	 1	 (Glut1)	 to	 facilitate	 glucose	 uptake;	 this	correlates	with	an	increase	in	glycolysis	(Pearce	and	Pearce,	2013).	To	examine	the	capacity	for	glucose	uptake	by	human	virus-specific	CD8	T	cells,	we	analysed	their	 expression	 of	 Glut1	 upon	 activation.	 First,	 we	 stimulated	 T	 cells	 from	chronically	 co-infected	 patients	 with	 HBV	 or	 CMV	 derived	 peptides	 for	 4hrs	directly	 ex	 vivo	 and	measured	Glut1	 expression	 on	 dextramer-positive	 T	 cells.	Glut1	expression	was	higher	in	activated	virus-specific	than	in	global	CD8	T	cells	(data	 not	 shown).	 Glut1	 expression	 was	 increased	 in	 HBV	 compared	 to	 CMV-specific	 T	 cells	 (Figure	 1a),	 suggesting	 that	 a	 defect	 in	 glucose	 uptake	 was	unlikely	 to	be	responsible	 for	 their	defective	cytokine	production	(Suppl	 figure	1a).		Since	HBV-specific	T	cells	from	the	circulation	can	only	be	detected	at	very	low	frequency	 we	 next	 expanded	 T	 cells	 in	 culture	 to	 study	 their	 metabolic	phenotype	 in	more	detail.	We	 confirmed	 that	 the	differences	 observed	 ex	 vivo	were	maintained	 in	vitro.	HBV	or	CMV-specific	CD8	were	stimulated	with	 their	cognate	peptides	and,	upon	restimulation,	identified	by	their	production	of	IFNγ	and	 co-stained	 for	 Glut1.	 Again,	 the	 frequency	 of	 Glut1	 expression	 in	 virus-specific	T	 cells	was	 significantly	 increased	above	 the	 amount	 expressed	by	 the	global	CD8	cells	 in	the	same	sample,	confirming	that	Glut1	is	upregulated	upon	antigen-specific	activation	(Fig1b,c).			
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We	then	compared	paired	HBV	and	CMV-specific	CD8	T	cell	responses	from	the	same	 donors,	 which	 had	 been	 activated	 to	 comparable	 levels	 as	 assessed	 by	CD38	expression	(Suppl	Fig1b).	The	frequency	of	Glut1	positive	cells	was	again	higher	for	HBV-specific	than	CMV-specific	CD8	in	these	paired	samples	(Fig1b,d).	We	observed	the	same	increased	expression	of	Glut1	in	HBV	compared	to	CMV,	when	cultured	specific	T	cells	were	detected	by	dextramer	staining	in	3	patients	with	known	responses	to	both	viruses	(Suppl	Fig1c).		To	 confirm	 that	 increased	 Glut1	 expression	 was	 mediating	 increased	 glucose	uptake,	we	pulsed	virus-specific	T	cells	with	the	fluorescent	glucose	analogue	2-NBDG	at	the	end	of	culture.	Increased	expression	of	Glut1	was	accompanied	by	an	increase	in	the	uptake	of	2-NBDG	(Fig1e,f	and	correlation	in	Suppl	Fig1d).				
Glut1	 upregulation	 is	 associated	with	 T	 cell	 exhaustion	 and	 can	 be	 promoted	 by	
hypoxic	conditions	mimicking	the	hepatic	milieu.			Since	 the	 increased	 Glut1	 expression	 and	 glucose	 uptake	 on	 poorly	 functional	HBV-specific	CD8	was	paradoxical,	we	postulated	that	it	might	relate	to	their	site	of	 antigen	 encounter	 in	 vivo.	 HBV	 only	 replicates	 in	 the	 liver,	 an	 immune	suppressive	 environment	 where	 T	 cells	 have	 restricted	 supplies	 of	 oxygen	(Jungermann	and	Kietzmann,	 2000).	Glut1	 expression	was	 indeed	 increased	 in	paired	 patient-derived	 CD8	 T	 cells	 from	 liver	 biopsies	 compared	 to	 PBMC	directly	ex	vivo.	 In	one	HLA-A2+	patient	we	detected	HBV-specific	CD8	T	cells,	confirming	increased	Glut1	in	the	liver	compared	to	the	periphery	(Fig	2a,b).	We	next	 recapitulated	 the	 hypoxic	 environment	 in	 vitro	 by	 stimulating	 HBV	 and	CMV-specific	T	cells	in	normoxic	versus	hypoxic	conditions	(5%	oxygen	to	mimic	
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the	 concentration	 in	 the	 hepatic	 circulation;	 (Jungermann	 and	 Kietzmann,	2000)).	Glut1	expression	was	promoted	in	hypoxic	conditions	(Fig	2c),	an	effect	which	was	independent	of	the	amount	of	T	cell	proliferation	(Suppl	Fig2a).	It	is	therefore	 possible	 that	 a	 phenotype	 favouring	 glycolysis	 might	 represent	 a	feedback	 response	 promoted	 by	 the	 hepatic	 environment	 in	 which	 T	 cells	encounter	their	antigen.			A	 hallmark	 of	 exhaustion	 is	 the	 co-inhibitory	 receptor	 PD-1	 (Wherry,	 2011),	which	is	highly	expressed	on	HBV-specific	T	cells	(Ferrari,	2015).	We	found	that	even	 during	 culture,	 HBV-specific	 CD8	 maintained	 higher	 levels	 of	 PD-1,	accompanied	by	 lower	expansion	and	 reduced	production	of	 IFNγ+,	 than	CMV-specific	CD8	(Suppl	Fig2b,c;	(Schurich	et	al.,	2013).	This	is	consistent	with	recent	work	showing	that	the	exhausted	phenotype	is	stable	(Utzschneider	et	al.,	2013).		Antigen-stimulated	 HBV-responses	 showed	 a	 correlation	 between	 their	expression	of	PD-1	and	Glut1	(Fig2d),	suggesting	that	exhausted	T	cells	increase	Glut1	 expression.	 Furthermore,	 we	 found	 a	 significant	 inverse	 correlation	between	Glut1	expression	and	the	magnitude	of	T	cell	expansion,	such	that	HBV-specific	 cells	 from	patients	with	 the	 lowest	 frequency	 responses	expressed	 the	highest	 levels	 of	 Glut1	 (Fig2e).	 This	 did	 not	 apply	 to	 CMV-specific	 T	 cells,	 for	which	 there	 was	 no	 significant	 correlation	 between	 Glut1	 and	 magnitude	 of	response	in	culture	(Fig2f).			To	 further	 probe	 the	 metabolic	 phenotype	 of	 patient-derived	 T	 cells,	 we	measured	cellular	oxygen	consumption	rates	during	a	mitochondrial	stress	test.	The	extremely	low	circulating	frequency	of	HBV-specific	T	cells	precluded	their	
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use	for	this	type	of	biochemical	analysis.	PD-1	is	expressed	on	recently	activated,	and	maintained	on	exhausted,	CD8	T	cells	 in	chronic	viral	 infections	(Barber	et	al.,	2005)	 including	HBV	(Boni	et	al.,	2007;	Fisicaro	et	al.,	2010;	Schurich	et	al.,	2013).	Studying	the	impact	of	PD-1	on	global	CD8	T	cell	metabolism	in	patients	with	 persistent	 viral	 infections	 is	 of	 importance	 since	 therapeutic	 blockade	 of	this	pathway	(currently	considered	in	HBV	following	recent	successes	in	cancer)	will	affect	all	PD-1+	cells.	We	therefore	sorted	PD-1+	and	PD-1−	CD8	T	cells	and	found	 that	 both	 fractions	 utilised	 glycolysis	 and	 OXPHOS,	 as	 measured	respectively	 by	 their	 extracellular	 acidification	 rate	 (ECAR)	 and	 oxygen	consumption	 rate	 (OCR),	 to	 varying	 degrees	 in	 the	 3	 patients	 tested	 (Suppl	Fig2d).	However,	the	spare	respiratory	capacity	(SRC),	calculated	as	percentage	change	in	mean	OCR	at	baseline	to	maximal	OCR	upon	treatment	with	FCCP	was	lower	in	PD-1+	compared	to	PD-1−	CD8	T	cells	(Fig2g,h),	a	feature	retained	when	cultured	 in	 vitro	 (Suppl	 Fig2e).	 SRC	 is	 a	 measure	 of	 maximal	 mitochondrial	capacity	available	to	a	cell	(Henson	et	al.,	2014),	therefore	the	low	SRC	suggests	that	PD-1+	T	cells	are	 less	well	equipped	to	 function	 in	conditions	of	 increased	energy	 demand.	 The	 low	 SRC	 in	 PD-1+	 cells	 was	 at	 odds	 with	 the	 higher	abundance	of	memory	cells	in	this	population	(Suppl	Fig2f),	described	to	be	high	utilisers	 of	 OXPHOS	 (van	 der	 Windt	 et	 al.,	 2012).	 Our	 findings	 therefore	reinforced	 the	 potential	 relevance	 of	 PD-1	 expression,	 rather	 than	 T	 cell	differentiation	state,	as	a	driver	of	the	metabolic	changes	observed.				
HBV-specific	T	cells	are	dependent	on	glycolysis	for	immediate	effector	function	To	 further	 examine	 the	 paradoxical	 increase	 in	 glucose	 uptake	 by	 exhausted	HBV-specific	T	cells,	we	tested	their	dependence	on	glycolysis	to	provide	energy.		
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To	 this	 end	 we	 stimulated	 T	 cells	 in	 media	 containing	 galactose	 instead	 of	glucose,	to	prevent	them	efficiently	utilising	glycolysis	(Chang	et	al.,	2013).	After	expansion	 in	 regular	 media,	 cells	 were	 split	 into	 either	 glucose	 or	 galactose	containing	media	to	assess	the	requirement	for	glycolysis	for	immediate	effector	function	upon	antigenic	restimulation.			CMV-specific	cells	showed	a	diverse	response	to	glucose	deprivation,	with	IFNγ	production	in	some	patients	being	completely	unaffected	or	even	increased	and	in	others	being	decreased	(Fig3a,b).	Overall	the	frequency	of	IFNγ+	CMV-specific	CD8	 in	 the	 presence	 of	 galactose	 compared	 to	 glucose	 was	 slightly	 reduced,	whilst	 overall	 the	 amount	 of	 IFNγ	 produced	 per	 cell	 was	 unaffected	 (Suppl	Fig3a).	 In	 contrast,	 the	 IFNγ	 response	 of	 HBV-specific	 cells	 declined	 strikingly	upon	culture	in	galactose	(Fig3a,b)	with	IFNγ	MFI	also	decreasing	(Suppl	Fig3a).	Thus	HBV-specific	CD8	showed	significantly	more	dependence	on	glycolysis	than	CMV-specific	 CD8	 when	 mounting	 an	 immediate	 effector	 response	 (Fig3b).		Similarly	the	frequency	of	T	cells	able	to	produce	tumour	necrosis	factor	(TNF)	upon	peptide	restimulation	 in	galactose	was	more	affected	 in	HBV-	(p=0.0005)	than	CMV-specific	(p=0.0399)	responses	(Fig3c).			We	next	asked	whether	there	was	an	association	between	Glut1	expression	and	the	 ability	 of	 virus-specific	 cells	 to	mediate	 effector	 function	 in	 the	 absence	 of	glucose.	 We	 therefore	 split	 our	 cohort	 into	 patients	 where	 the	 response	 was	more	 severely	 affected,	 (reduction	 in	 IFNγ	 frequency	 below	 the	 mean	 of	 the	cohort,	 grey	 shaded	 area	 Figure	 3b),	 and	 those	where	 the	 response	 remained	above	the	mean	of	the	cohort.	HBV-specific	responses	most	affected	by	blocking	
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glycolysis	had	significantly	more	Glut1+	cells	then	those	that	were	less	affected,	while	 a	 non-significant	 difference	 was	 observed	 for	 CMV-specific	 cells	 (Suppl	Fig3b).	These	data	suggest	that	the	upregulation	of	Glut1	reflects	a	dependence	on	glycolysis	in	exhausted	T	cells.			The	finding	that	HBV-specific	T	cells	were	unable	to	utilise	OXPHOS	for	effector	function,	 prompted	us	 to	 investigate	whether	 they	 had	 a	mitochondrial	 defect.	Mitochondrial	 mass	 (MM)	 can	 be	 assessed	 by	 staining	 cells	 with	 the	mitochondrial	potential-independent	dye	mitoTracker	green,	previously	used	to	assess	the	presence	of	enlarged	non-functional	mitochondria	in	T	cells	(Henson	et	al.,	2014).	HBV-specific	CD8	showed	a	higher	mitochondrial	mass	compared	to	CMV-specific	 CD8	 from	 the	 same	 donors	 (Fig3d).	 The	 increased	mitochondrial	mass	in	HBV	compared	to	CMV	specific	CD8	was	also	apparent	ex	vivo	(Fig3e).		We	 then	 used	 the	 ratiometric	 fluorescent	 dye	 JC-1	 to	 assess	 mitochondrial	potential,	a	key	readout	of	mitochondrial	function.	HBV-specific	T	cells	showed	a	much	lower	mitochondrial	potential	than	CMV-specific	cells,	as	indicated	by	the	drop	 in	 the	 red/green	 fluorescence	 intensity	 ratio	 of	 the	 probe,	 which	 is	independent	of	mitochondrial	size	or	shape	(Fig3f).	A	decrease	in	mitochondrial	potential	 could	 be	 a	 sign	 of	 apoptosis	 induction,	 however	 we	 found	 HBV	 and	CMV-specific	T	cells	to	be	viable	as	they	were	negative	for	dead	cell	staining	and	showed	low	Annexin	V	staining,	comparable	to	global	T	cells	in	the	same	culture	(Suppl	 Fig3c).	 This	 indicates	 that	mitochondrial	 dysfunction	 in	 HBV-specific	 T	cells	limits	their	capacity	to	fuel	their	energy	demand	for	cytokine	production	by	switching	to	OXPHOS.		
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The	third	signal	cytokine	IL-12	enhances	the	metabolic	function	of	exhausted	HBV-
specific	T	cells		We	recently	demonstrated	that	the	third	signal	pro-inflammatory	cytokine	IL-12	enhanced	effector	responses	in	exhausted	HBV-specific	T	cells,	while	it	had	little	effect	on	the	 functional	CMV-specific	response.	When	HBV-specific	T	cells	were	stimulated	 with	 viral	 peptide	 in	 the	 presence	 of	 IL-12,	 IFNγ	 production,	 TNF	production	and	cytotoxicity	were	significantly	 increased	(Schurich	et	al.,	2013).	We	 postulated	 that	 the	 capacity	 of	 IL-12	 to	 reconstitute	 HBV-specific	 T	 cell	effector	function	might	be	mediated	by	a	change	in	the	efficiency	of	their	glucose	metabolism.			To	test	this,	we	stimulated	and	cultured	cells	in	T	cell	media	in	the	presence	or	absence	of	IL-12	and	restimulated	in	the	presence	of	either	glucose	or	galactose.	When	IL-12	enhanced	IFNγ	production	by	HBV-specific	T	cells,	the	cytokine	did	so	 irrespective	 of	 whether	 the	 cells	 were	 restimulated	 in	 glucose	 or	 galactose	(Fig4a,b).	 Furthermore,	 IL-12	 stimulated	 HBV-specific	 CD8	 had	 a	 significantly	increased	 ratio	 of	 polarised	 compared	 to	 depolarised	 mitochondria	 (Fig4c).	These	 findings	 indicate	 that	 IL-12	 can	 stimulate	 mitochondrial	 and	 metabolic	changes	 in	 exhausted	 HBV-specific	 T	 cells,	 reversing	 their	 dependence	 on	glycolysis	for	effector	function.		 	
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Discussion	
	Glycolysis,	 accompanied	 by	 the	 upregulation	 of	 the	 glucose	 transporter	 Glut1,	has	been	described	to	be	the	main	metabolic	pathway	fuelling	effector	function	upon	 T	 cell	 activation	 (MacIver	 et	 al.,	 2013).	 Surprisingly,	 we	 found	 that	exhausted	 HBV-specific	 T	 cells,	 which	 have	 very	 limited	 effector	 capacity,	showed	 a	 marked	 increase	 in	 expression	 of	 functional	 Glut1	 upon	 antigenic	stimulation,	 suggesting	 that	 their	 impaired	 effector	 function	 was	 not	 due	 to	 a	lack	 of	 glucose	 uptake.	 In	 contrast	 to	 HBV-specific	 CD8,	 analysis	 of	 paired	samples	 revealed	 that	 the	 more	 functional	 CMV-specific	 CD8	 expressed	 less	Glut1,	despite	equivalent	 levels	of	antigenic	reactivation.	This	 implied	that	HBV	and	CMV-specific	T	 cells	might	 utilise	different	metabolic	 pathways.	We	 tested	this	 hypothesis	 by	 culturing	 the	 cells	 in	 galactose,	which	 impairs	 glycolysis,	 to	probe	 the	capacity	of	cells	 to	use	 the	alternative	pathway	of	generating	energy	via	mitochondrial	 OXPHOS	 (Chang	 et	 al.,	 2013).	We	 found	 that	HBV	 and	 CMV-specific	 T	 cells	 are	 differentially	 affected	 by	 this	method	 of	 favouring	OXPHOS	over	glycolysis.	CMV-specific	CD8	T	cells	from	many	patients	produced	normal	or	even	elevated	amounts	of	effector	cytokines	upon	culture	 in	galactose,	while	 in	others	the	production	declined,	but	was	never	completely	abrogated.	These	data	do	 not	 contradict	 previous	 findings	 regarding	 the	 importance	 of	 glycolysis	 for	IFNγ	production	in	CD4	T	cells	(Chang	et	al.,	2013).	In	HBV-specific	cells,	effector	cytokine	 production	 declined	 or	 was	 completely	 lost.	 Defects	 in	 the	 glycolytic	pathway	cannot	be	formally	excluded	but	our	data	suggest	that	exhausted	HBV-specific	 T	 cells	 rely	 on	 generating	 their	 energy	 through	 glycolysis	 and	 cannot	compensate	by	using	other	pathways.	Our	 findings	 suggest	 that	 in	 some	virus-
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specific	 effector	 T	 cells,	 mitochondrial	 respiration	 is	 used	 to	 supplement	glycolysis	in	order	to	satisfy	the	demands	of	efficient	cytokine	production;	in	line	with	increased	proliferation,	survival	and	anti-viral	function	in	CD8	T	cells	with	genetically	 enhanced	 OXPHOS	 (Okoye	 et	 al.,	 2015).	 The	 generation	 of	 reactive	oxygen	species	(ROS)	 is	vital	 in	the	activation	of	CD4	T	cells	(Sena	et	al.,	2013)	and	an	inability	of	HBV-specific	T	cells	to	use	OXPHOS	could	partially	be	due	to	changes	in	ROS	production.	However,	we	did	not	find	a	significant	difference	in	the	 production	 of	 ROS	 in	 exhausted	 compared	 to	 functional	 CD8	 (data	 not	shown).		The	observed	 inability	of	HBV-specific	CD8	T	cells	 to	use	OXPHOS	 to	 fuel	 their	effector	function	pointed	to	a	mitochondrial	defect.	This	was	supported	by	their	increased	 mitochondrial	 depolarisation	 compared	 to	 CMV-specific	 T	 cells,	indicative	of	impaired	function.	Additionally,	an	increase	in	mitochondrial	mass	in	HBV-	 compared	 to	 CMV-specific	 CD8	 could	 be	 due	 to	 the	 formation	 of	 non-functional	 giant	 mitochondria,	 as	 have	 been	 described	 to	 accumulate	 in	terminally	differentiated	human	CD8	T	cells	(Henson	et	al.,	2014).			We	found	that	the	most	exhausted	T	cells,	as	measured	by	decrease	in	cytokine	production	and	increase	in	co-inhibitory	PD-1,	showed	the	highest	expression	of	Glut1	 and	 the	 lowest	 ability	 to	maintain	 effector	 functions	when	 forced	 to	 use	OXPHOS.	 Our	 data	 therefore	 reveal	 that	 functional	 exhaustion	 is	 linked	 to	metabolic	 impairments	 in	 human	 virus-specific	 CD8	 T	 cells.	 This	 link	 is	underscored	by	the	impact	of	IL-12;	its	capacity	to	rescue	HBV-specific	CD8	from	exhaustion	and	enhance	their	functionality	(Schurich	et	al.,	2013)	is	paralleled	by	an	 increased	 proportion	 of	 cells	 harbouring	 polarised	 mitochondria	 and	 a	
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reduction	in	their	dependence	on	glycolysis.	Of	note,	we	have	previously	shown	that	IL-12	can	reduce	PD-1	expression	on	CD8	T	cells	(Schurich	et	al.,	2013)	and	the	contribution	of	this	pathway	to	the	metabolic	changes	observed	is	currently	under	investigation.		Global	 patient-derived	 PD-1+	 CD8	 T	 cells	 had	 a	 low	 SRC	 suggesting	 that	 their	ability	to	generate	additional	energy	through	oxygen	consumption	in	situations	of	metabolic	stress	is	reduced.	PD-1	signalling	has	previously	been	described	to	reduce	 glycolysis	 and	 promote	 fatty	 acid	 oxidation	 in	 global	 CD4	 T	 cells	(Patsoukis	et	al.,	2015)	but	 the	 impact	of	PD-1	signalling	on	 the	metabolism	of	exhausted	CD8	 cells	 remains	 to	be	 investigated.	 It	 is	 also	 important	 to	keep	 in	mind	 that	 T	 cells	 in	 patients	 with	 chronic	 HBV	 express	 additional	 inhibitory	molecules	 like	 Tim-3	 and	 CTLA-4	 (Nebbia	 et	 al.,	 2012;	 Schurich	 et	 al.,	 2011),	therefore	multiple	signals	might	shape	the	altered	metabolism	in	these	cells.		It	 will	 be	 interesting	 to	 establish	 whether	 exhausted	 T	 cells	 in	 other	 settings		(HIV	 or	 HCV	 infection,	 tumours)	 have	 a	 similar	 deficiency	 in	 their	 capacity	 to	supplement	 glycolysis	 with	 OXPHOS	 in	 order	 to	 optimise	 their	 energy	 supply.	The	mitochondrial	defects	and	adaptation	to	glycolysis	that	we	documented	here	may	 be	 the	 result	 of	 particular	 features	 of	 chronic	 HBV,	 such	 as	 high-level	antigenic	stimulation	in	the	immunosuppressive	liver	environment.	In	particular	the	 hypoxic	milieu	 of	 the	 liver	may	 be	 relevant	 since	 hypoxia	 inducible	 factor	(HIF-1α/β)	 induces	 the	 transcription	 of	 Glut1	 and	 multiple	 rate-limiting	glycolytic	enzymes	to	sustain	glycolysis	in	activated	T	cells	(Finlay	et	al.,	2012).	We	 found	 that	 intrahepatic	T	cells	showed	an	 increased	expression	of	Glut1	ex	vivo	 and	 that	 hypoxia	 during	 antigenic	 stimulation	 in	 vitro	 could	 recapitulate	
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this	 upregulation.	 The	 liver	 can	 produce	 IL-7	 in	 response	 to	 TLR	 signalling,	thereby	enhancing	T	cell	survival	and	function	(Sawa	et	al.,	2009);	it	is	plausible	this	 could	 be	 partially	 mediated	 by	 the	 capacity	 of	 IL-7	 to	 drive	 glycolysis	through	the	induction	of	Glut1	(Loisel-Meyer	et	al.,	2012;	Wofford	et	al.,	2008).	The	 metabolic	 phenotype	 of	 HBV-specific	 T	 cells	 could	 therefore	 be	 a	consequence	of,	or	an	adaptation	to,	their	target	environment,	allowing	the	few	remaining	responses	to	survive.				In	summary,	our	data	show	that	different	virus-specific	T	cells	in	the	same	host	have	contrasting	usage	of	pathways	for	glucose	metabolism.	The	exhausted	T	cell	response	directed	against	HBV	is	characterised	by	an	upregulation	of	the	glucose	transporter	 Glut1,	 a	 dependency	 on	 glycolysis	 and	 mitochondrial	 defects	 in	OXPHOS	 and	 depolarisation.	 Instead,	 the	 highly	 functional	 CMV-specific	 T	 cell	response	 can	 utilise	 OXPHOS	 for	 effector	 function	 when	 glycolysis	 is	 blocked.	Our	 finding	 that	 a	 more	 protective	 T	 cell	 response	 requires	 mitochondrial	respiration	is	consistent	with	two	recent	papers	emphasising	the	importance	of	OXPHOS	 for	 antigen-specific	 T	 cell	 expansion	 and	 antiviral	 immunity	 in	 mice	(Okoye	 et	 al.,	 2015;	 Sena	 et	 al.,	 2013).	 A	 better	 understanding	 of	 why	 this	pathway	 fails	 in	 exhausted	 T	 cells	 may	 reveal	 mitochondrial	 targets	 for	therapeutic	boosting	of	antiviral	immunity.			
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Experimental	Procedures	
	
Patients		
Ethics	 statement:	 This	 study	 was	 approved	 by	 the	 ethical	 boards	 of	 the	 Royal	Free	 Hospital	 and	 Camden	 Primary	 Care	 and	 written	 informed	 consent	 was	obtained	 from	all	participants. All	participants	were	HCV	and	HIV	seronegative	and	HBV	 treatment-naïve.	HLA-A2	 status	was	 determined	 by	 specific	 antibody	(AbD	Serotec).	Patient	information	is	provided	in	Supplementary	Table	1. 	
 
Over	night	and	short-term	cell	culture	and	stimulation	PBMC	 were	 isolated	 by	 Ficoll-Hypaque	 density	 gradient	 centrifugation	 and	either	 analysed	 directly	 or	 cryopreserved.	 Liver	 biopsy	 sections,	 surplus	 to	diagnostic	 requirements,	were	homogenised	and	 filtered	 to	obtain	 intrahepatic	lymphocytes.	To	examine	virus-specific	T	 cell	 responses,	PBMCs	 from	HLA	A2+	donors	 were	 stimulated	 with	 1µM	 HBV-derived	 HLA-A2	 restricted	 peptides	(core	 FLPSDFFPSV,	 envelope	 FLLTRILTI,	 WLSLLVPFV,	 LLVPFVQWFV,	GLSPTVWLSV,	 polymerase	 GLSRYVARL,	 KLHLYSHPI)	 (Proimmune)	 or	 stained	with	 dextramers	 loaded	 with	 the	 above	 peptides	 (Immudex).	 If	 derived	 from	HLA-A2-	 donors	 with	 1µg	 overlapping	 peptides	 spanning	 the	 whole	 HBV	 core	protein,	 sequence	 correlating	 to	 HBV	 genotype	 D	 (AYW)	 	 (JPT	 Peptide	Technologies).	 Responses	 to	 CMV	 were	 measured	 using	 1µM	 NLVPMVATV	peptide	 (Proimmune)	 or	 dextramers	 (Immudex)	 for	 HLA-A2+	 donors	 or	overlapping	 pp65	 for	 HLA-A2-	 donors	 (JPT	 Peptide	 Technologies).	 All	 cultures	were	supplemented	with	20U/ml	rhIL-2	(Miltenyi	Biotech)	at	Day	0	and	4	with	addition	 of	 rhIL-12	 (Miltenyi	 Biotech)	 at	 10ng/ml	 at	 Day	 0	 where	 indicated.	
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PBMCs	were	restimulated	on	day	9	for	4hrs	by	re-adding	peptide	at	the	original	concentration	 in	 the	presence	of	1µg/ml	Brefeldin	A	 (BFA,	 Sigma-Aldrich).	 	 To	assess	metabolic	 requirements,	 samples	were	 split	 and	 transferred	 into	media	containing	 either	 10mM	glucose	 or	 10mM	galactose	 (supplemented	with	 1mM	sodium	pyruvate)	on	day	8	 for	24hrs;	peptide	and	BFA	was	added	for	 the	 final	4hrs.	Virus-specific	responses	were	identified	by	IFNγ	or	TNFα	production.		
	
Impact	of	hypoxia	PBMC	were	cultured	and	peptide	stimulated	as	above	at	normoxia	(21%	02).	At	the	end	of	culture	PBMC	were	split	and	peptide	restimulated	in	the	presence	of	BFA	 over	 night	 at	 5%	 O2	 (hypoxia)	 or	 21%	 O2	 (normoxia).	 Virus-specific	responses	were	identified	by	IFNγ.	
	
Flow	cytometric	analysis	PBMCs	 were	 stained	 for	 surface	 markers,	 CD8	 (OKT8),	 CD3	(UCHT1)(eBiosciences),	 PD-1	 (EH12.2H7)	 (Biolegend),	 CD38	 (HIT2)	 (BD	Biosciences)	 Dead	 cells	 were	 always	 excluded	 using	 live/dead	 fixable	 dye	staining	 kit	 (Invitrogen).	 Cells	 were	 fixed	 and	 permeabilized	 for	 detection	 of	intracellular	molecules	using	anti	 IFNγ (B27),	TNFα	 (MAB11)	(BD	Biosciences),	Glut1	(202915)	(RnD	Systems).	JC-1	2µM	(Molecular	Probes),	mitotracker	green	100nM	 (Invitrogen)	 used	 as	 per	 manufacturer’s	 instruction.	 Samples	 were	acquired	on	a	BD	Fortess,	analysis	was	performed	using	Flowjo	(Tree	Star).	
	
Metabolic	Assay	
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OCR	and	ECAR	were	measured	on	a	XF-24	Extracellular	Flux	Analyser	(Seahorse	Bioscience).	 CD8	 T	 cells	 were	 stimulated	 with	 1µg/ml	 CD3	 (OKT3)	(eBiosciences)	 and	 20U/ml	 IL-2	 in	 non-buffered	 RPMI	 during	 the	 assay.	Inhibitors	 were	 used	 at	 1µM	 oligomycin,	 1.5µM	 fluorocarbonyl	 cyanide	phenylhydrazone	 (FCCP),	 1µM	 antimycinA	 (Sigma	 Aldrich)	 100nM	 rotenone	(Seahorse	Bioscience).		
Statistical	analysis	Statistical	analyses	were	performed	using	the	non-parametric	Mann-Whitney	or	Wilcoxon	matched	pairs	 test	as	appropriate	and	significant	differences	marked	on	figures	((*	=	p<0.05;	**	=	p<0.005;	***	=	p<0.0005).	
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Figure	Legends	
	
Figure	1:	Increased	expression	of	Glut-1	on	HBV-specific	compared	to	CMV-specific	
CD8	T	cells	a)	Glut1	expression	in	HBV	and	CMV-specific	T	cells	after	4hrs	stimulation	with	cognate	 peptide	 directly	 ex	 vivo.	 Example	 of	 virus-specific	 cells	 detected	 by	staining	 with	 HLA-A2+	 dextramers	 loaded	 with	 virus-specific	 or	 irrelevant	control	peptides	(left	panel),	overlay	of	Glut1	MFI	in	HBV	and	CMV-specific	cells	(middle)	and	summary	data	(right	panel).	 (b)	Glut1	expression	 in	global	CD8	T	cells	(left	panel),	IFNγ	response	upon	culture	with	HBV	or	CMV-specific	peptides	(middle	 panel)	 and	 Glut1	 expression	 on	 virus-specific	 IFNγ CD8	 T	 cells	 (right	panel).	Summary	data	comparing	%Glut1+	T	cells	in	global	and	HBV-specific	CD8	T	cells	(c)	and	HBV	and	CMV-specific	T	cells	(d)	in	paired	samples.	Comparison	of	Glut1	expression	and	2-NBDG	uptake	in	IFNγ+ HBV	and	CMV-specific	CD8	T	cells,	example	(e)	and	summary	data	(f).		
Figure	 2:	 CD8	 T	 cell	 Glut1	 expression	 can	 be	 induced	 by	 hypoxia	 and	 correlates	
with	an	exhausted	phenotype		Glut1	 expression	 in	 HBV-specific	 CD8	 T	 cells,	 detected	 by	 HLA-A2	 dextramer	staining	 in	 paired	 PBMC	 and	 intrahepatic	 lymphocytes	 (IHL)	 directly	 ex	 vivo,	gated	 for	 CD3+CD8+CD4-	 T	 cells	 	 (a).	 Summary	 data	 of	 Glut1	 expression	 on	global	CD8	T	cells	from	PBMC	and	IHL	(b).	PBMC	were	cultured	and	restimulated	with	specific	peptides	on	day	10	for	16hrs	in	hypoxic	(5%	O2)	or	normoxic	(21%	O2)	 conditions	 to	analyse	Glut1	mean	 fluorescence	 intensity	 (MFI)	 in	HBV	and	CMV-specific	 T	 cells	 (c).	 Glut1	 MFI	 was	 plotted	 against	 expression	 of	 (d)	 co-
	 24	
inhibitory	PD-1,	(e)	%IFNγ+	HBV-specific	T	cells	and	(f)	%IFNγ+	CMV-specific	T	cells	(d).	Oxygen	consumption	rate	(OCR)	of	purified	patient-derived	PD-1+	and	PD-1−	CD8	T	cells	were	measured	in	real	time	ex	vivo.	Cells	were	stimulated	with	anti-CD3	and	IL-2	at	the	time	of	analysis	and	mitochondrial	inhibitors	added	as	indicated	 (oligomycin	 blocking	 ATP	 synthesis	 through	 complex	 V,	 FCCP	which	uncouples	 ATP	 synthesis	 from	 the	 electron	 transport	 chain	 by	 transporting	electrons	 across	 the	 inner	mitochondrial	membrane	 and	 rotenone/antimycinA	blocking	 complex	 I	 and	 III)	 representative	 example	 (g).	 The	 spare	 respiratory	capacity	 (SRC)	 was	 calculated	 as	 percentage	 change	 in	 mean	 baseline	 OCR	 to	mean	maximal	OCR	after	the	addition	of	FCCP	in	the	three	patients	tested	in	two	independent	experiments	(h).				
Figure	 3:	 CMV	 but	 not	 HBV-specific	 CD8	 T	 cells	 can	 maintain	 effector	 cytokine	
production	when	glucose	is	withdrawn	PBMC	 were	 cultured	 in	 complete	 T	 cell	 media,	 before	 transferring	 them	 into	media	 containing	 either	 10mM	 glucose	 or	 10mM	 galactose	 for	 24hrs	 before	restimulation.	 Representative	 example	 (a)	 and	 summary	 data	 showing	 the	magnitude	 of	 the	 virus-specific	 (b)	 IFNγ	 and	 (c)	 TNF	 response	 in	 galactose,	plotted	as	fold	reduction	compared	to	response	in	glucose	(set	to	one,	indicated	as	 line	 in	 the	 graph).	 Mean	 response	 is	 shown	 as	 grey	 bars	 and	 individual	responses	as	dots.	Comparison	of	mitochondrial	mass	in	cultured	HBV	and	CMV-specific	 T	 cells	 by	 mitotracker	 green	 staining,	 representative	 histograms	 and	summary	 data	 (d)	 and	 in	 dextramer+	 virus-specific	 T	 cells	 ex	 vivo	 after	 4hrs	stimulation	with	cognate	peptide;	representative	histograms	and	summary	data	(e).	 Determination	 of	 mitochondrial	 polarisation	 state	 by	 staining	 with	 the	
	 25	
ratiometric	 dye	 JC-1.	Red	 JC-1	 staining	 indicates	polarised	mitochondria,	while	loss	 of	 red	 fluorescence	 shows	 depolarisation,	 example	 FACS	 plot	 and	comparison	of	the	ratio	of	polarised/	depolarised	mitochondria	in	HBV	and	CMV-specific	T	cells	from	the	same	patients	(f).		
Figure	 4:	 Stimulation	 with	 the	 pro-inflammatory	 cytokine	 IL-12	 recovers	 HBV-
specific	responses	even	when	glycolysis	is	suppressed	PBMC	were	stimulated	with	HBV-derived	peptides	in	the	presence	or	absence	of	IL-12,	 cultured	 for	 9	 days	 and	 transferred	 into	media	 containing	 either	 10mM	glucose	or	10mM	galactose	for	24hrs	before	peptide	restimulation	for	functional	analysis.	 Representative	 FACS	 plots	 of	 the	 percentage	 of	 IFNγ+	 CD8	 when	cultured	in	glucose	or	galactose	and	stimulated	with	HBV	peptides	+/-	IL-12	or	IL-12	 alone	 (a).	 Summary	 data	 showing	 the	 IFNγ	 response	 to	HBV	 peptides	 in	galactose	 alone,	 galactose	with	 IL-12	or	 glucose	with	 IL-12,	 plotted	 as	 the	 fold	change	compared	to	the	response	of	cells	stimulated	in	glucose	alone	(set	to	one,	indicated	 as	 line	 in	 the	 graph).	 The	mean	 response	 is	 shown	 as	 grey	 bars	 and	individual	 responses	 as	 dots	 (b).	 Change	 in	 mitochondrial	 polarisation	 upon	stimulation	of	HBV-specific	T	cells	with	IL-12,	representative	staining	with	JC-1	(left)	 and	 summary	 data	 comparing	 the	 ratio	 of	 polarised	 to	 depolarised	mitochondria	(right)	(c).			
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Supplementary	Figure	1,	related	to	Figure	1:	HBV	and	CMV-specific	T	cells	retain	
distinct	phenotypes	in	culture	Summary	data	of	paired	HBV-and	CMV-specific	T	 cells	 from	patients	with	CHB	detected	 ex	 vivo	 through	 HLA-A2	 dextramer	 staining	 and	 then	 stimulated	 for	4hrs	with	cognate	peptide	to	induce	IFNγ	production	(a)	and	after	10day	culture:	activation	 status	 assessed	 by	 %CD38	 expression	 of	 IFNγ+	 CD8	 (b).	 Glut1	expression	 in	 virus-specific	 CD8	 T	 cells,	 detected	 through	 HLA-A2	 dextramer	staining	 (c).	Correlation	of	 the	 fold	 change	 in	HBV	compared	 to	CMV	mediated	glucose	uptake	with	the	fold	change	in	Glut1	expression	between	the	two	subsets	(d).			
Supplementary	Figure	2,	 related	 to	Figure	2:	Metabolic	profile	of	patient-derived	
PD-1+	and	PD-1	negative	CD8	T	cells	ex	vivo	and	after	culture		Glut1	 expression	 is	 independent	 of	 proliferation,	 representative	 CMV-response	(left)	 and	CFSE	profile	 (cells	divided	over	night	 in	5%	oxygen)	 (middle),	Glut1	expression	is	compared	in	the	25%	most	highly	divided	(grey	shaded)	and	25%	least	divided	(black	line)	cells	and	summary	(far	right)	(a).	Expression	of	the	co-inhibitory	 receptor	 PD-1	 on	 IFNγ+	 CD8	 (b)	 and	 frequency	 (%)	 and	 amount	 of	IFNγ	produced	(mean	fluorescence	intensity	MFI)	by	CD8	(c).	Comparison	of	PD-1+	 and	 PD-1-	 CD8	 T	 cells	 stimulated	 with	 anti-CD3	 and	 IL-2	 ex	 vivo.	 Oxygen	consumption	 rate	 (OCR)	 and	 extracellular	 acidification	 rate	 (ECAR)	 were	measured	 in	 real	 time	 (mean	 of	 4	 base	 line	 readings	 shown)	 (d).	 Example	 of	metabolic	profile	of	PD-1+	and	PD-1	negative	CD8	T	cells	after	10day	culture	 in	
vitro.	Cells	were	stimulated	with	anti-CD3	and	IL-2	during	measurement	of	OCR	and	 mitochondrial	 inhibitors	 added	 as	 indicated	 (e).	 Differentiation	 status	 of	
	 2	
global	 PD-1+	 and	 PD-1	 negative	 CD8	 T	 cells	 in	 chronic	 HBV	 defined	 as	 naïve:	CD45RA+,	CD27+,	central	memory	(CM)	CD45RA-,	CD27+,	effector	memory	(EM)	CD45RA-,	CD27-	and	terminally	differentiated	(EMRA)	CD45RA+,	CD27-	(f).		
Supplementary	 Figure	 3,	 related	 to	 Figure	 3:	 CD8	 expressing	 high	 Glut1	 are	 the	
most	dependent	on	glycolysis.		(a)	 Summary	 data	 showing	 the	 IFNγ	 MFI	 of	 the	 virus-specific	 response	 upon	restimulation	 in	 galactose,	 plotted	 as	 fold	 change	 compared	 to	 response	 in	glucose	 (set	 to	 one	 as	 indicated	 by	 line	 in	 the	 graph).	 The	 mean	 response	 is	shown	 as	 grey	 bars	 and	 individual	 responses	 as	 dots.	 (b)	 Glut1	 expression	 in	IFNγ+	 HBV-specific	 T	 cells	 (left	 panel)	 or	 CMV-specific	 T	 cells	 (right	 panel),	divided	according	to	whether	the	response	to	culture	galactose	is	above	or	below	the	mean	(all	samples	falling	in	grey	shaded	area	in	Fig3b	left	panel).	(c)	Staining	with	the	apoptosis	marker	Annexin	V	in	global,	virus-specific	and	apoptotic	dead	cells	within	 the	 same	wells	 (n=6).	 (d)	Model	of	metabolism	 in	 functional	CMV-specific	compared	to	exhausted	HBV-specific	CD8	T	cells.			
Supplementary	table	1,	related	to	materials	and	methods			
 Number Gender (m) Age HBV DNA (IU/ml) ALT (U/L) eAg+ 
CHB patients 132 77 35 (18-64) 825 (1-300,000,000) 31 (10-250) 16 	Patient	characteristics.	Data	shown	is	the	median	value	and	spread	from	lowest	to	highest	values	in	brackets.	In	cases	where	viral	load	was	below	quantification	the	value	was	set	to	1.	
